<p>坎伯兰制药（NASDAQ:CPIX - 获取免费报告）于周二发布了季度财报。这家专业制药公司报告的季度每股收益为（$0.13），符合分析师的共识预期（$0.13），FiscalAI 报道。坎伯兰制药的股本回报率为 5.04%，净利润率为 -6.37%。该公司本季度的收入为 913 万美元，而共识预期为 850 万美元。</p>
<p>以下是坎伯兰制药电话会议的主要要点：</p>
<ul>
<li>坎伯兰与 <strong>Apotex</strong> 签署了一项变革性协议，以 1 亿美元现金加上 900 万美元的库存、过渡费用和里程碑费用出售其美国品牌商业组合，管理层表示这将显著增强资产负债表，并为转向以开发为重点的战略提供资金。</li>
<li>第一季度来自市场品牌的收入为 910 万美元（不包括之前的一次性里程碑，增长约 5%），GAAP 净亏损约为 330 万美元，调整后亏损为 190 万美元（$0.13/股）；经营现金流为正 387,000 美元，手头现金为 1100 万美元。</li>
<li>以 <strong>ifetroban</strong> 为主的临床管道显示出进展——约 1400 名受试者已用药，FDA 获得 <strong>快速通道</strong> 及孤儿/罕见儿科指定用于杜氏肌营养不良症，硬皮病的入组已完成，正在进行的 IPF 试验经过中期安全审查后获准继续，预计今年晚些时候将有中期疗效结果。</li>
<li>商业和制造方面的胜利包括 FDA 扩大 <strong>Caldolor</strong>（术后疼痛）的标签，FDA 批准制造地点以便于计划中的 <strong>Vaprisol</strong> 今年重新上市，推出 Talicia 销售推广，以及首批 Vibativ 运往中国——管理层表示这些举措将在组合出售前扩大患者的获取渠道。</li>
</ul>
<h2>坎伯兰制药股价上涨 0.4%</h2>
<p>周二，CPIX 的股票在交易时段上涨 0.02 美元，达到 4.55 美元。该公司的交易量为 318,892 股，而其平均交易量为 787,554 股。该公司的市值为 6807 万美元，市盈率为 -23.95，贝塔值为 -0.06。该股票的 50 日移动平均价格为 3.45 美元，200 日移动平均价格为 3.42 美元。该公司的速动比率为 0.84，流动比率为 1.01，债务与股本比率为 0.21。坎伯兰制药的 52 周低点为 1.85 美元，52 周高点为 6.26 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家大型投资者最近调整了对该股票的持有。Perceptive Advisors LLC 在第四季度购买了价值约 1,358,000 美元的坎伯兰制药新头寸。Marshall Wace LLP 在第四季度购买了价值约 192,000 美元的坎伯兰制药新头寸。Geode Capital Management LLC 在第四季度将其在坎伯兰制药的持股增加了 5.6%。Geode Capital Management LLC 现在拥有 107,274 股该专业制药公司的股票，价值 427,000 美元，此前在此期间又购买了 5,653 股。Two Sigma Investments LP 在第三季度将其在坎伯兰制药的持股增加了 16.5%。Two Sigma Investments LP 现在拥有 37,591 股该专业制药公司的股票，价值 117,000 美元，此前在此期间又购买了 5,326 股。最后，Dimensional Fund Advisors LP 在第三季度将其在坎伯兰制药的持股增加了 11.1%。Dimensional Fund Advisors LP 现在拥有 280,869 股该专业制药公司的股票，价值 876,000 美元，此前在此期间又购买了 27,980 股。对冲基金和其他机构投资者持有该公司 15.51% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票研究分析师对该公司发表了看法。Wall Street Zen 在 3 月 14 日的研究报告中将坎伯兰制药的评级从 “持有” 上调至 “买入”。Weiss Ratings 在 3 月 27 日的研究报告中重申了对坎伯兰制药股票的 “卖出（d-）” 评级。根据 MarketBeat 的数据，一位股票研究分析师对该股票给予了卖出评级，坎伯兰制药的平均评级为 “卖出”。</p>
<p><strong>获取我们对 CPIX 的最新分析</strong></p>
<h2>坎伯兰制药公司简介</h2>
<p>（获取免费报告）</p>
<p>坎伯兰制药公司 NASDAQ: CPIX 是一家总部位于田纳西州纳什维尔的专业制药公司，专注于医院和急救产品的开发、制造和商业化。公司成立于 1993 年，建立了一个旨在满足急救医学、重症监护病房和其他医院环境中关键护理需求的品牌治疗组合。坎伯兰的战略强调许可和收购具有已建立安全性和有效性但市场覆盖有限的产品，然后利用其销售网络扩大其商业足迹。</p>
<p>该公司的旗舰产品包括 Acetadote（N-乙酰半胱氨酸注射液），这是 FDA 批准的唯一用于静脉注射的对乙酰氨基酚过量的解毒剂；Vasostrict（加压素注射液），用于提高患有血管扩张性休克的成人的血压；Cerebrex（双氯芬酸钠注射液），用于管理急性疼痛和发热的抗炎药；以及 Dynastat（帕瑞昔布钠），用于术后疼痛缓解的 COX-2 抑制剂。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比坎伯兰制药更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUNQSVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUNQSVg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在坎伯兰制药吗？</h2>
<p>在考虑坎伯兰药业之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而坎伯兰药业并不在名单上。</p>
<p>虽然坎伯兰药业目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

坎伯兰药业

<p>坎伯兰药业（NASDAQ:CPIX）报告每股收益为（$0.13），符合分析师的预期。该公司实现收入为 913 万美元，超过 850 万美元的预估。坎伯兰与 Apotex 签署了一项价值 1 亿美元的协议，以出售其美国品牌组合，增强了其资产负债表。该公司的股本回报率为 5.04%，净利润率为负 6.37%。股价上涨 0.4%，至 4.55 美元，机构投资者增加了持股。分析师的评级不一，其中一项评级上调至 “买入”，平均评级为 “卖出”</p>

<p>Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.13), FiscalAI reports. Cumberland Pharmaceuticals had a positive return on equity of 5.04% and a negative net margin of 6.37%.The business had revenue of $9.13 million for the quarter, compared to the consensus estimate of $8.50 million.</p>
<div class="lb-trans"><p>坎伯兰制药（NASDAQ:CPIX - 获取免费报告）于周二发布了季度财报。这家专业制药公司报告的季度每股收益为（$0.13），符合分析师的共识预期（$0.13），FiscalAI 报道。坎伯兰制药的股本回报率为 5.04%，净利润率为 -6.37%。该公司本季度的收入为 913 万美元，而共识预期为 850 万美元。</p>
</div><p>Here are the key takeaways from Cumberland Pharmaceuticals' conference call:</p>
<div class="lb-trans"><p>以下是坎伯兰制药电话会议的主要要点：</p>
</div><ul>
<li>Cumberland signed a transformational deal with <strong>Apotex</strong> to sell its U.S. branded commercial portfolio for <strong>$100 million</strong> cash plus $9 million for inventory, transition fees and a milestone, which management says will materially strengthen the balance sheet and fund a shift to a development-focused strategy.</li>
<li>First‑quarter revenue from marketed brands was $9.1 million (up ~5% excluding a prior one‑time milestone), with a GAAP net loss of ~$3.3 million and an adjusted loss of $1.9 million ($0.13/share); operating cash flow was positive $387,000 and cash on hand was $11 million.</li>
<li>The clinical pipeline, led by <strong>ifetroban</strong>, shows progress—~1,400 subjects dosed, FDA <strong>Fast Track</strong> plus Orphan/Rare Pediatric designations for Duchenne muscular dystrophy, completed enrollment in scleroderma, and ongoing IPF trials with an interim safety review clearing continuation and interim efficacy expected later this year.</li>
<li>Commercial and manufacturing wins include FDA expanded labeling for <strong>Caldolor</strong> (post‑operative pain), FDA clearance of the manufacturing site enabling a planned <strong>Vaprisol</strong> relaunch this year, launch of Talicia sales promotion, and the first shipment of Vibativ to China—moves management says will broaden patient access prior to the portfolio sale.</li>
</ul>
<div class="lb-trans"><ul>
<li>坎伯兰与 <strong>Apotex</strong> 签署了一项变革性协议，以 1 亿美元现金加上 900 万美元的库存、过渡费用和里程碑费用出售其美国品牌商业组合，管理层表示这将显著增强资产负债表，并为转向以开发为重点的战略提供资金。</li>
<li>第一季度来自市场品牌的收入为 910 万美元（不包括之前的一次性里程碑，增长约 5%），GAAP 净亏损约为 330 万美元，调整后亏损为 190 万美元（$0.13/股）；经营现金流为正 387,000 美元，手头现金为 1100 万美元。</li>
<li>以 <strong>ifetroban</strong> 为主的临床管道显示出进展——约 1400 名受试者已用药，FDA 获得 <strong>快速通道</strong> 及孤儿/罕见儿科指定用于杜氏肌营养不良症，硬皮病的入组已完成，正在进行的 IPF 试验经过中期安全审查后获准继续，预计今年晚些时候将有中期疗效结果。</li>
<li>商业和制造方面的胜利包括 FDA 扩大 <strong>Caldolor</strong>（术后疼痛）的标签，FDA 批准制造地点以便于计划中的 <strong>Vaprisol</strong> 今年重新上市，推出 Talicia 销售推广，以及首批 Vibativ 运往中国——管理层表示这些举措将在组合出售前扩大患者的获取渠道。</li>
</ul>
</div><h2>Cumberland Pharmaceuticals Trading Up 0.4%</h2>
<div class="lb-trans"><h2>坎伯兰制药股价上涨 0.4%</h2>
</div><p>Shares of CPIX traded up $0.02 during trading hours on Tuesday, hitting $4.55. The company had a trading volume of 318,892 shares, compared to its average volume of 787,554. The firm has a market cap of $68.07 million, a P/E ratio of -23.95 and a beta of -0.06. The stock's 50 day moving average price is $3.45 and its 200 day moving average price is $3.42. The company has a quick ratio of 0.84, a current ratio of 1.01 and a debt-to-equity ratio of 0.21. Cumberland Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $6.26.</p>
<div class="lb-trans"><p>周二，CPIX 的股票在交易时段上涨 0.02 美元，达到 4.55 美元。该公司的交易量为 318,892 股，而其平均交易量为 787,554 股。该公司的市值为 6807 万美元，市盈率为 -23.95，贝塔值为 -0.06。该股票的 50 日移动平均价格为 3.45 美元，200 日移动平均价格为 3.42 美元。该公司的速动比率为 0.84，流动比率为 1.01，债务与股本比率为 0.21。坎伯兰制药的 52 周低点为 1.85 美元，52 周高点为 6.26 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new position in shares of Cumberland Pharmaceuticals in the fourth quarter worth about $1,358,000. Marshall Wace LLP purchased a new position in shares of Cumberland Pharmaceuticals in the fourth quarter worth about $192,000. Geode Capital Management LLC increased its holdings in shares of Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company's stock worth $427,000 after buying an additional 5,653 shares during the period. Two Sigma Investments LP increased its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company's stock worth $117,000 after buying an additional 5,326 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company's stock worth $876,000 after buying an additional 27,980 shares during the period. Hedge funds and other institutional investors own 15.51% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了对该股票的持有。Perceptive Advisors LLC 在第四季度购买了价值约 1,358,000 美元的坎伯兰制药新头寸。Marshall Wace LLP 在第四季度购买了价值约 192,000 美元的坎伯兰制药新头寸。Geode Capital Management LLC 在第四季度将其在坎伯兰制药的持股增加了 5.6%。Geode Capital Management LLC 现在拥有 107,274 股该专业制药公司的股票，价值 427,000 美元，此前在此期间又购买了 5,653 股。Two Sigma Investments LP 在第三季度将其在坎伯兰制药的持股增加了 16.5%。Two Sigma Investments LP 现在拥有 37,591 股该专业制药公司的股票，价值 117,000 美元，此前在此期间又购买了 5,326 股。最后，Dimensional Fund Advisors LP 在第三季度将其在坎伯兰制药的持股增加了 11.1%。Dimensional Fund Advisors LP 现在拥有 280,869 股该专业制药公司的股票，价值 876,000 美元，此前在此期间又购买了 27,980 股。对冲基金和其他机构投资者持有该公司 15.51% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded Cumberland Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 14th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Cumberland Pharmaceuticals has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>一些股票研究分析师对该公司发表了看法。Wall Street Zen 在 3 月 14 日的研究报告中将坎伯兰制药的评级从 “持有” 上调至 “买入”。Weiss Ratings 在 3 月 27 日的研究报告中重申了对坎伯兰制药股票的 “卖出（d-）” 评级。根据 MarketBeat 的数据，一位股票研究分析师对该股票给予了卖出评级，坎伯兰制药的平均评级为 “卖出”。</p>
</div><p><strong>Get Our Latest Analysis on CPIX</strong></p>
<div class="lb-trans"><p><strong>获取我们对 CPIX 的最新分析</strong></p>
</div><h2>Cumberland Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>坎伯兰制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.</p>
<div class="lb-trans"><p>坎伯兰制药公司 NASDAQ: CPIX 是一家总部位于田纳西州纳什维尔的专业制药公司，专注于医院和急救产品的开发、制造和商业化。公司成立于 1993 年，建立了一个旨在满足急救医学、重症监护病房和其他医院环境中关键护理需求的品牌治疗组合。坎伯兰的战略强调许可和收购具有已建立安全性和有效性但市场覆盖有限的产品，然后利用其销售网络扩大其商业足迹。</p>
</div><p>The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.</p>
<div class="lb-trans"><p>该公司的旗舰产品包括 Acetadote（N-乙酰半胱氨酸注射液），这是 FDA 批准的唯一用于静脉注射的对乙酰氨基酚过量的解毒剂；Vasostrict（加压素注射液），用于提高患有血管扩张性休克的成人的血压；Cerebrex（双氯芬酸钠注射液），用于管理急性疼痛和发热的抗炎药；以及 Dynastat（帕瑞昔布钠），用于术后疼痛缓解的 COX-2 抑制剂。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Cumberland Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比坎伯兰制药更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BJWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CPIX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cumberland Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在坎伯兰制药吗？</h2>
</div><p>Before you consider Cumberland Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑坎伯兰药业之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而坎伯兰药业并不在名单上。</p>
</div><p>While Cumberland Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然坎伯兰药业目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

坎伯兰药业（NASDAQ:CPIX）公布财报结果